Lukas Reitzle

Dr. Lukas Reitzle


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2023 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
FTFalko Tesch
Falko Tesch
FEFranz Ehm
Franz Ehm
AVAnnika Vivirito
Annika Vivirito
DWDanny Wende
Danny Wende
MBManuel Batram
Manuel Batram
JSJochen Schmitt
Jochen Schmitt
Objectives: To investigate whether the risk of developing an incident autoimmune disease is increased in patients with prior COVID-19 disease compared to those without COVID-19, a large cohort study was conducted. Method: A cohort was selected from German routine health care data. Based on documented diagnoses, we identified individuals with polymerase chain reaction (PCR)-confirmed COVID-19 through December 31, 2020. Patients were matched 1:3 to control patients without COVID-19. Both groups were followed up until June 30, 2021. We used the four quarters preceding the index date until the end of follow-up to analyze the onset of autoimmune diseases during the post-acute period. Incidence rates (IR) per 1000 person-years were calculated for each outcome and patient group. Poisson models were deployed to estimate the incidence rate ratios (IRRs) of developing an autoimmune disease conditional on a preceding diagnosis of COVID-19. Results: In total, 641,704 patients with COVID-19 were included. Comparing the incidence rates in the COVID-19 (IR=15.05, 95% CI: 14.69–15.42) and matched control groups (IR=10.55, 95% CI: 10.25–10.86), we found a 42.63% higher likelihood of acquiring autoimmunity for patients who had suffered from COVID-19. This estimate was similar for common autoimmune diseases, such as Hashimoto thyroiditis, rheumatoid arthritis, or Sjögren syndrome. The highest IRR was observed for autoimmune diseases of the vasculitis group. Patients with a more severe course of COVID-19 were at a greater risk for incident autoimmune disease. Conclusions: SARS-CoV-2 infection is associated with an increased risk of developing new-onset autoimmune diseases after the acute phase of infection. Key Points• In the 3 to 15 months after acute infection, patients who had suffered from COVID-19 had a 43% (95% CI: 37–48%) higher likelihood of developing a first-onset autoimmune disease, meaning an absolute increase in incidence of 4.50 per 1000 person-years over the control group.• COVID-19 showed the strongest association with vascular autoimmune diseases.

LRLukas Reitzle
Lukas Reitzle
CSChristian Schmidt
Christian Schmidt
FFFrancesca Färber
Francesca Färber
LHLena Huebl
Lena Huebl
LWLothar Heinz Wieler
Lothar Heinz Wieler
CHChristin Heidemann
Christin Heidemann
During the COVID-19 pandemic in Germany, non-pharmaceutical interventions were imposed to contain the spread of the virus. Based on cross-sectional waves in March, July and December 2020 of the COVID-19 Snapshot Monitoring (COSMO), the present study investigated the impact of the introduced measures on the perceived access to health care. Additionally, for the wave in December, treatment occasion as well as utilization and satisfaction regarding telemedicine were analysed. For 18–74-year-old participants requiring medical care, descriptive and logistic regression analyses were performed. During the less strict second lockdown in December, participants reported more frequently ensured access to health care (91.2%) compared to the first lockdown in March (86.8%), but less frequently compared to July (94.2%) during a period with only mild restrictions. In December, main treatment occasions of required medical appointments were check-up visits at the general practitioner (55.2%) and dentist (36.2%), followed by acute treatments at the general practitioner (25.6%) and dentist (19.0%), treatments at the physio-, ergo- or speech therapist (13.1%), psychotherapist (11.9%), and scheduled hospital admissions or surgeries (10.0%). Of the participants, 20.0% indicated utilization of telemedical (15.4% telephone, 7.6% video) consultations. Of them, 43.7% were satisfied with the service. In conclusion, for the majority of participants, access to medical care was ensured during the COVID-19 pandemic; however, access slightly decreased during phases of lockdown. Telemedicine complemented the access to medical appointments.

10 February 2023 in Deutsches Ärzteblatt international
Verified
Journal Article
Closed access
LRLukas Reitzle
Lukas Reitzle
CHChristin Heidemann
Christin Heidemann
JBJens Baumert
Jens Baumert
MKMatthias Kaltheuner
Matthias Kaltheuner
HAHeinke Adamczewski
Heinke Adamczewski
CSChrista Scheidt-Nave
Christa Scheidt-Nave
Diabetes mellitus (DM) is a major risk factor for complications of pregnancy. Based on information for all inpatient births in Germany, we assessed the risks for selected pregnancy complications in women with pregestational diabetes mellitus (preDM) or gestational diabetes mellitus (GDM). The underlying data comprised all singleton births contained in the inpatient perinatal medicine quality assurance statistics for the years 2013–2019. The frequencies of premature birth, elevated birth weight (large for gestational age, LGA), cesarean section, transfer of the newborn to the perinatal unit, and stillbirth were stratified by maternal age and diabetes status (preDM, GDM, no DM). Poisson regression was used to calculate the relative risks (RR) with 95% confidence intervals (95% CI) for the whole period and for each individual year in women with preDM or GDM relative to women without DM. Among the 4 991 275 singleton births included, GDM was documented in 283 210 (5.7%) and preDM in 46 605 (0.93%) cases. GDM was associated with higher RR for premature birth (1.13 [1.12; 1.15]), LGA (1.57 [1.55; 1.58]), cesarean section (1.26 [1.25; 1.27]), and transfer of the newborn (1.54 [1.52; 1.55]). These associations were even stronger in women with preDM: premature birth (2.13 [2.08; 2.18]), LGA (2.72 [2.67; 2.77]), cesarean section (1.62 [1.60; 1.64]), transfer of the newborn (2.61 [2.56; 2.66]). PreDM increased the risk of stillbirth (RR: 2.34 [2.11; 2.59]); GDM was associated with a lower risk (RR: 0.67 [0.62; 0.72]). For women with preDM, the risk of pregnancy complications increased over the study period. GDM and preDM are still associated with elevated risks of pregnancy complications. In the case of preDM, the risks may be attributable to the fact that the hyperglycemia is more severe and is already present before conception. Continuous monitoring should include risk factors in pregnant women and care-relevant aspects.

2 June 2022 in Das Gesundheitswesen
Verified
Journal Article
Closed access
PDF file
LRLukas Reitzle
Lukas Reitzle
PIPeter Ihle
Peter Ihle
CHChristin Heidemann
Christin Heidemann
RPRebecca Paprott
Rebecca Paprott
IKIngrid Köster
Ingrid Köster
CSChristian Schmidt
Christian Schmidt
Zusammenfassung: Hintergrund Diabetes mellitus ist eine Erkrankung von hoher Public-Health-Relevanz. Zur Schätzung der zeitlichen Entwicklung der Prävalenz kommen auch Routinedaten der gesetzlichen Krankenversicherung zum Einsatz. In diesen primär zu Abrechnungszwecken generierten Daten stellt die Definition von Erkrankungen eine besondere methodische Herausforderung dar. In der vorliegenden Studie wurde ein Algorithmus zur Unterscheidung von Typ-1- und Typ-2-Diabetes für die Analyse von Routinedaten entwickelt. Methodik Datengrundlage ist eine alters- und geschlechtsstratifizierte Zufallsstichprobe der Versicherten der Barmer mit einer durchgehenden Versicherungsdauer von 2010 bis 2018 in der Größenordnung von 1% der deutschen Bevölkerung. Ein Diabetes wurde im Berichtsjahr 2018 definiert als Dokumentation (1) einer gesicherten ICD-Diagnose E10.- bis E14.- im ambulanten Sektor in mindestens 2 Quartalen, (2) einer gesicherten ICD-Diagnose E10.- bis E14.- in einem Quartal mit einer zusätzlichen Antidiabetikaverordnung (ATC-Codes A10) oder (3) einer ICD-Diagnose E10.- bis E14.- im stationären Sektor, dem ambulanten Operieren oder der Arbeitsunfähigkeit. Anhand der ICD-Diagnosen E10.- bis E14.- und der verordneten Arzneimittel, unterschieden nach Insulin und anderen Antidiabetika, wurden die Personen einem Diabetestypen zugeordnet. Nicht eindeutige oder widersprüchliche Konstellationen wurden anhand des Alters, der Häufigkeit sowie überjährigen Betrachtung der Diagnosedokumentation zugeordnet. Die Einschreibung in ein Disease-Management-Programm wurde in einer Sensitivitätsanalyse berücksichtigt. Ergebnisse Die Prävalenz des dokumentierten Diabetes in der Stichprobe der Barmer betrug im Jahr 2018 8,8%. Anhand des Algorithmus konnten 98,5% der Personen mit Diabetes dem Typ-1-Diabetes (5,5%), dem Typ-2-Diabetes (92,6%) oder einer weiteren spezifischen Diabetesform (0,43%) zugeordnet werden. Somit ergaben sich für das Jahr 2018 Prävalenzen von 0,48% für den Typ-1-Diabetes und 8,1% für den Typ-2-Diabetes. Schlussfolgerung Bereits anhand weniger Merkmale wie Diagnosen, Arzneimittelverordnung und dem Alter lässt sich die große Mehrzahl der Personen mit Diabetes einem Typ zuordnen. In weiterführenden Studien sollte im Abgleich mit Primärdaten die externe Validität geprüft werden. So ermöglicht der Algorithmus die Auswertung wichtiger epidemiologischer Kennzahlen und der Häufigkeit von Folge- und Begleiterkrankungen auf Basis von Routinedaten differenziert nach Typ-1- und Typ-2-Diabetes, welche in der Surveillance des Diabetes zukünftig berücksichtigt werden sollen.

2 September 2020 in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Verified
Journal Article
Open access
PDF file
LRLukas Reitzle
Lukas Reitzle
CSChristian Schmidt
Christian Schmidt
YDYong Du
Yong Du
AIAndrea Icks
Andrea Icks
BHBernd Hagen
Bernd Hagen
CSChrista Scheidt-Nave
Christa Scheidt-Nave
Zusammenfassung: Hintergrund: Datengrundlagen für systematische, fortlaufende Analysen zur Häufigkeit mikrovaskulärer Komplikationen von Diabetes mellitus in Deutschland sind bislang nur begrenzt vorhanden. Erstmals wurde geprüft, ob Versichertendaten aller gesetzlichen Krankenversicherungen (GKV) nach Datentransparenzverordnung hierfür geeignet sind. Methode: Analysiert wurden die GKV-Versichertendaten der Berichtsjahre 2012 und 2013. Die Bezugspopulation wurde identifiziert: Versicherte mit Diabetes, definiert als Dokumentation mindestens zweier ambulanter oder einer stationären Diabetesdiagnose gemäß der Internationalen Klassifikation der Krankheiten (ICD-Codes E10–E14). Komplikationen wurden anhand folgender ICD-Codes definiert: Nephropathie (N08.3), Retinopathie (H36.0), Polyneuropathie (G63.2), diabetisches Fußsyndrom (DFS; E10-14.74, E10-14.75), chronische Niereninsuffizienz (N18.-) und Dialysebehandlung (Z49.1, Z49.2, Z99.2). Die Ergebnisse wurden mit Prävalenzschätzungen aus Routine- und Registerdaten in Deutschland und im Ausland verglichen. Ergebnisse: Im Jahr 2013 wurde für 6,6 Mio. GKV-Versicherte ein Diabetes dokumentiert (2012: 6,5 Mio.). Die chronische Niereninsuffizienz stellte die häufigste Komplikation im Jahr 2013 dar (15,0 %), gefolgt von diabetischer Polyneuropathie (13,5 %), Nephropathie (7,6 %), Retinopathie (7,0 %), DFS (6,1 %) und Dialysebehandlung (0,56 %). Während Ergebnisse zu diabetischer Retinopathie, Nephropathie und Polyneuropathie im Vergleich zu anderen Prävalenzschätzungen für Personen mit Typ-2-Diabetes niedriger ausfielen, sind diese zu Niereninsuffizienz, Dialysebehandlung und DFS vergleichbar. Schlussfolgerung: Verstetigte Analysen der GKV-Daten sind von hohem Wert für die Diabetes-Surveillance, erfordern jedoch vertiefende Analysen zur Überprüfung und Vereinheitlichung von Falldefinitionen und Dokumentationsverhalten.

16 June 2021
Verified
Report
Open access
PDF file
LRLukas Reitzle
Lukas Reitzle
CSChristian Schmidt
Christian Schmidt
CHChristin Heidemann
Christin Heidemann
AIAndrea Icks
Andrea Icks
MKMatthias Kaltheuner
Matthias Kaltheuner
CSChrista Scheidt-Nave
Christa Scheidt-Nave
Gestational diabetes mellitus (GDM) is an important risk factor for pregnancy complications. Since 2012, the Federal Joint Committee’s maternity directive recommends a two-step screening for GDM with a pre-test and subsequent diagnostic test if the pre-test is positive. This study analyses the implementation and development over time of GDM screening participation and prevalence in Germany. The data basis is the external inpatient obstetrics quality assurance documentation, which covers all births in hospital. Women with diabetes before pregnancy were excluded. The study defined women as GDM cases if the condition was documented in maternity records or if the ICD-10 diagnosis O24.4 was coded for inpatients at discharge and figures were determined for the years 2013 to 2018. As the documentation of screening tests has only been included in the data set since 2016, screening participation for the years 2016 to 2018 were estimated and evaluated based on the pre-test and/or diagnostic tests documented in maternity records. In 2018, the majority of all women who gave birth in hospitals had had a pre-test conducted (65.0%) or a pre-test and diagnostic test (18.2%) in line with the two-step procedure. A further 6.7% received a diagnostic test alone. GDM screening participation increased over time from 83.4% in 2016 to 89.9% in 2018. The prevalence of a documented GDM increased from 4.6% to 6.8% between 2013 and 2018. In 2018, this equates to 51,318 women with GDM. Reliably assessing the extent and causes of this development will require continuous analyses of screening implementation, documentation and changes in maternal risk factors.